Apricus Biosciences Announces First Patient Enrolled in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud's Phenomenon

SAN DIEGO, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the first patient has been enrolled in the Phase 2a clinical trial to evaluate RayVa ™ , Apricus' product candidate for the treatment of Raynaud's phenomenon secondary to scleroderma. RayVa combines alprostadil, a potent vasodilator, with Apricus' proprietary permeation enhancer DDAIP.HCl, and is applied as an on-demand topical cream to affected extremities.

"Raynaud's phenomenon is a near universal feature of scleroderma and causes pain, loss of hand function and is associated with fingertip ulcerations and loss of finger substance. A topical therapy such as RayVa has the ability to improve blood flow locally without systemic adverse effects and has the potential to alleviate symptoms and possibly prevent finger injury," said Dr. James R. Seibold, an internationally recognized researcher in both scleroderma and Raynaud's phenomenon and the Principal Member of Scleroderma Research Consultants, LLC.

The randomized, double-blind, placebo-controlled, Phase 2a clinical trial is expected to enroll approximately 45 patients with Raynaud's phenomenon secondary to scleroderma. Each patient will receive applications of placebo and one of three different doses of RayVa, in a crossover design. This dose-ranging study will evaluate hemodynamics, skin temperature at the site of application, as measured by Laser Doppler and thermography, and symptomatic response following a standardized cold challenge. Other endpoints include safety and pharmacokinetic assessments.

"The dosing of the first patient in the RayVa Phase 2a clinical trial is a significant milestone for the Company, and importantly, for Raynaud's patients, as we seek to address with RayVa, the symptoms associated with this chronic condition," said Rich Pascoe, Chief Executive Officer. "Moreover, with the expected completion of the RayVa Phase 2a clinical trial, coupled with the anticipated start of the Phase 2b clinical trial of fispemifene in the first half of 2015 in men with secondary hypogonadism, Apricus is well positioned to drive value from its development-stage pipeline next year."

About RayVa™

RayVa is the proprietary name for Apricus' product candidate for the treatment of Raynaud's phenomenon associated with scleroderma (systemic sclerosis). The RayVa product combines alprostadil (prostaglandin E1), a potent vasodilator, with Apricus' proprietary permeation enhancer, and is applied as an on-demand topical cream to affected extremities. Apricus initiated a Phase 2a clinical trial following promising animal data. RayVa may qualify for FDA Priority Review, given the unmet medical need and lack of approved products in the United States to treat secondary Raynaud's phenomenon in patients with systemic sclerosis. Apricus anticipates submitting a New Drug Application for RayVa as early as 2017.

About Raynaud's Phenomenon

Raynaud's phenomenon (RP) is characterized by vasoconstriction in response to cold or stress of the hands and feet, resulting in reduced blood flow and the sensation of pain, which can be severe. Primary Raynaud's phenomenon, which is not associated with an underlying medical condition, affects an estimated 3-5% of the US population. 1 Secondary Raynaud's phenomenon, is driven by an underlying medical condition, such as scleroderma, lupus or rheumatoid arthritis. 2 Symptoms are severe and patients risk associated fingertip ulcerations. There are an estimated 100,000 adult patients with scleroderma in the US 3 , of which approximately 90% have secondary Raynaud's phenomenon 2 . Overall, there are approximately 500,000 adult patients with secondary Raynaud's phenomenon in the US. 2, 4

Approximately 80% of scleroderma patients are women. 5 Both primary and secondary Raynaud's phenomenon disproportionately affects women. 6 There is currently no approved therapy for Raynaud's phenomenon in the United States, representing an unmet medical need.

About Apricus Biosciences, Inc .

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus' lead product, Vitaros ® , for the treatment of erectile dysfunction, is approved in Europe and Canada and commercialized in several countries in Europe. Apricus' marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus' second-generation Vitaros room temperature device is under development and is expected to enhance the product's commercial value. Apricus recently commenced a Phase 2a trial for RayVa™, Apricus' product candidate for the treatment of Raynaud's phenomenon. Femprox ® , Apricus' product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. Apricus is currently seeking a strategic partner for Femprox. In October 2014, Apricus gained U.S. development and commercialization rights for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms, in Phase 2 development.

For further information on Apricus, visit http://www.apricusbio.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: statements regarding the ability of Apricus' management team to successfully carry out planned development programs for fispemifene and RayVa ™ ; references to the timing of the commencement of a Phase 2b clinical trial for fispemifene and the submission of a New Drug Application for RayVa. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: results of future clinical trials of fispemifene and RayVa; potential adverse side effects or other safety risks associated with fispemifene and RayVa that could delay or preclude approval; Apricus' ability to obtain and maintain intellectual property protection for RayVa, fispemifene or any other product candidates; Apricus' ability to obtain additional financing in order to complete the development and commercialization of its product candidates; Apricus' ability to attract and retain senior management and key scientific personnel, which are necessary to successfully carry out planned development and operate Apricus' business; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

1 Wigley FM. Raynaud's phenomenon. N Engl J Med. 2002; 347:1001–1008.

2 Pope JE. The Diagnosis and Treatment of Raynaud's Phenomenon. Drugs 2007; 67: 517-525.

3 Barnes J and Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012, 24:165–170.

American College of Rheumatology ( http://www.rheumatology.org/Practice/Clinical...cleroderma ).

4 2012 U.S. Census Bureau: State and County QuickFacts ( http://quickfacts.census.gov/qfd/states/00000.html ).

5 Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, Hummers LK, Wigley FM. Race and Association With Disease Manifestations and Mortality in Scleroderma. Medicine 2013; 92: 191-205.

6 National Institutes of Health ( http://www.nhlbi.nih.gov/health/health-topics...aud/atrisk ).

Steve Martin Apricus Biosciences Chief Financial Officer (858) 222-8041 Institutional Investors: Angeli Kolhatkar Media: Justin Jackson Burns McClellan (212) 213-0006 Retail Investors: Chris Eddy, David Collins Catalyst Global (212) 924-9800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 163

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 127

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 151

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 142

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 24

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

GroupBy and adCAPTCHA: A New Era for eCommerce Security

Updated Category News Views 110

Strengthening eCommerce with Cutting-Edge Technology GroupBy Inc., a pioneering SaaS provider in eCommerce search and product discovery, recently announced a vital partnership with adCAPTCHA, a state-of-the-art security verification platform. This collaboration focuses on enhancing digital customer experiences while ensuring robust security measures are in place. The...

Continue Reading
Frost & Sullivan Boosts China Insight with LeadLeo

Updated Category News Views 90

Navigating China's Complex Market Landscape You've got to understand, the stakes in China are like a high-wire act—mystifying and risky, yet bountiful if you play your cards right. Frost & Sullivan's latest maneuver into China's business intel scene is basically the lifeline for navigating this increasingly convoluted market. With China surging ahead in AI, biotech, and...

Continue Reading
Important Update for MoonLake Immunotherapeutics Investors

Updated Category News Views 171

Update for MoonLake Immunotherapeutics Investors Investors in MoonLake Immunotherapeutics, known by its stock symbol MLTX, should pay attention to an important class action development that impacts their rights. It is crucial for individuals who purchased common stock during a designated time frame to understand their options and the benefits of securing legal...

Continue Reading
Upcoming Changes to the Issuing and Paying Agent at WisdomTree

Updated Category News Views 228

WisdomTree Multi Asset Issuer Public Limited Company, based in Ireland, made waves back in 2024 when it decided to switch up its Issuing and Paying Agent as part of an overhaul to improve its operations. Apex IFS Limited had been holding that title, but as the filing revealed, WisdomTree was ready for a change—a transition to Apex Fund Services (Ireland) Limited was on...

Continue Reading
Foxconn India Strengthens Manufacturing with Key Equipment Buy

Updated Category News Views 156

Foxconn India Makes a Strategic Equipment Acquisition Foxconn, a subsidiary of Hon Hai Precision Industry Co., Ltd., has made significant strides in enhancing its manufacturing capabilities in India. The company has successfully completed a notable acquisition of essential electromechanical equipment from CINDA ENGINEERING AND CONSTRUCTION PRIVATE LIMITED. This strategic...

Continue Reading